✨ Free AI Report
Calliditas Therapeutics AB: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Calliditas Therapeutics AB
Research Preview

Calliditas Therapeutics AB: Business Overview, Financials & Competitive Analysis

Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. T...

Analyst-debate audio for Calliditas Therapeutics AB

AskCyborg analysts argue the bull and bear cases for Calliditas Therapeutics AB across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Calliditas Therapeutics AB OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

A focused rare-disease biopharma with proven commercial traction in renal indications, backed by a large Japanese pharmaceutical...

Read the full analyst-debate transcript →
Industry Orphan Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 9, 2026
AI-Generated Research
30+ Page Report

Get the Latest Calliditas Therapeutics AB Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Calliditas Therapeutics AB Overview

Pro stress-test →

Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. The company specializes in rare renal and hepatic diseases, with TARPEYO (budesonide) as its commercial-stage lead product generating significant revenues.

Strategic Profile

Pro stress-test →

Calliditas Therapeutics AB (Nasdaq: CALT) is majority-owned by Asahi Kasei following its acquisition of over 90% of outstanding shares (September 2024). The company demonstrates strong commercial traction, with preliminary Net TARPEYO revenues of $100–102m for 2023, representing over 170% year-over-year growth compared to 2022.

Competitive Landscape

Pro stress-test →

Calliditas operates in the rare disease immunosuppressant space, competing indirectly with standard corticosteroid therapies and other emerging targeted treatments for autoimmune renal diseases. Primary differentiation derives from proprietary formulation (TARPEYO/Nefecon) that delivers budesonide directly to renal tissue, improving safety and efficacy profiles compared to systemic corticosteroids.

Industry Context

Calliditas Therapeutics AB operates in Orphan Drugs.

Key facts

Founded: 2004 · Headquarters: Stockholm, Sweden · Employees: N/A · Revenue: $100-102M · Market cap: $1.1B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Calliditas Therapeutics AB.

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Calliditas Therapeutics AB has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

IMPDH InhibitorsTreatment options for rare kidney diseases and anemia→CorticosteroidsStandard systemic immunosuppressants for renal indications→Immunosuppressive TherapiesBroad immunology and rare disease portfolio→

Compare Calliditas Therapeutics AB with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Calliditas Therapeutics AB operates in Orphan Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Orphan Drugs research →
NEW · MCP server

Ask your AI assistant about Calliditas Therapeutics AB

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Calliditas Therapeutics AB and its top competitor on Cyborg Score”
“What did Calliditas Therapeutics AB do this quarter?”
“Is Calliditas Therapeutics AB a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Calliditas Therapeutics AB do?+
Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. T...
What is Calliditas Therapeutics AB's Cyborg Score?+
Calliditas Therapeutics AB has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Calliditas Therapeutics AB's main competitors?+
Named competitors include IMPDH Inhibitors, Corticosteroids, Immunosuppressive Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Calliditas Therapeutics AB research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Calliditas Therapeutics AB research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Calliditas Therapeutics AB over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.